Alterations of plasma free fatty acids and glucose during labor

Whaley, William H.; Zuspan, Frederick P.; Nelson, George H.; Ahlquist, Raymond P.

doi:10.1016/0002-9378(67)90510-8

Cited by 20 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it is clear that the amino acid, L-arginine, is the sole substrate for NOS and thus is essential for NO production. It is estimated that the average diet is borderline in arginine content, 111,112 and circulating levels can be reduced by administration of arginine-deficient protein, 111,112 by pregnancy, [113][114][115][116][117] aging, 118 or stress. 118 Still, in vivo arginine levels have been thought to be more than sufficient for NO synthesis because at usual plasma levels of 50 to 100 mol/L, active transport produces intracellular levels of 1,000 mol/L, which vastly exceed the Km for NOS of 1 to 3 mol/L.…”

Section: No and Argininementioning

confidence: 99%

Medical Therapy for Pulmonary Arterial Hypertension

Badesch

Abman

Simonneau

et al. 2007

Chest

429

View full text Add to dashboard Cite

David B. Badesch, MD, FCCP; Steve H. Abman, MD; Gregory S. Ahearn, MD; Robyn J. Barst, MD; Douglas C. McCrory, MD, MHSc; Gerald Simonneau, MD; and Vallerie V. McLaughlin, MD, FCCP Pulmonary arterial hypertension (PAH) is often difficult to diagnose and challenging to treat. Untreated, it is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular failure and death. The past decade has seen remarkable improvements in therapy, driven largely by the conduct of randomized controlled trials. Still, the selection of most appropriate therapy is complex, and requires familiarity with the disease process, evidence from treatment trials, complicated drug delivery systems, dosing regimens, side effects, and complications. This chapter will provide evidence-based treatment recommendations for physicians involved in the care of these complex patients. Due to the complexity of the diagnostic evaluation required, and the treatment options available, it is strongly recommended that consideration be given to referral of patients with PAH to a specialized center. (CHEST 2004; 126:35S-62S)Key words: anticoagulation; arginine; beraprost; bosentan; calcium-channel blockers; endothelin; endothelin receptor antagonist; epoprostenol; idiopathic pulmonary arterial hypertension; iloprost; medical therapy; oxygen; primary pulmonary hypertension; prostacyclin; pulmonary arterial hypertension; pulmonary hypertension; secondary pulmonary hypertension; sildenafil; therapy; treatment; treprostinil; vasoreactivity; warfarin Abbreviations: cAMP ϭ cyclic adenosine monphosphate; CART ϭ combination antiretroviral therapy; CCB ϭ calcium-channel blocker; cGMP ϭ cyclic guanosine 3Ј-5Ј monophosphate; CI ϭ confidence interval; CO ϭ cardiac output; CTEPH ϭ chronic thromboembolic pulmonary hypertension; FDA ϭ Food and Drug Administration; INR ϭ international normalized ratio; IPAH ϭ idiopathic pulmonary arterial hypertension; mPAP ϭ mean pulmonary arterial pressure; NYHA ϭ New York Heart Association; NO ϭ nitric oxide; NOS ϭ nitric oxide synthase; PAH ϭ pulmonary arterial hypertension; PAP ϭ pulmonary arterial pressure; PH ϭ pulmonary hypertension; PPH ϭ primary pulmonary hypertension; PPHN ϭ persistant pulmonary hypertension of the newborn; PVR ϭ pulmonary vascular resistance; RCT ϭ randomized controlled clinical trial H istorically, medical treatment of pulmonary arterial hypertension (PAH) has been difficult. Idiopathic PAH (IPAH), formerly known as primary pulmonary hypertension (PPH), carried a very poor prognosis (median survival of approximately 2.8 years from the date of diagnosis) through the mid-1980s. Since then, a number of therapeutic options have been developed, with varying degrees of evidence to support their use. This chapter will review the current treatment of PAH, objectively detailing the evidence available to support each form of therapy. Some widely used therapies for PAH are generally accepted as being important and efficacious, although not supported by randomized controlled clini...

show abstract

Section: No and Argininementioning

confidence: 99%

Medical Therapy for Pulmonary Arterial Hypertension

Badesch

Abman

Simonneau

et al. 2007

Chest

429

View full text Add to dashboard Cite

show abstract

“…During normal labor, maternal blood glucose increases [17,23,25,26,39,58] which can be explained by the increased gluconeogenesis due to cortisol and adrenaline, produced as a stress reaction [19]. In prolonged labor, however, a decrease in maternal glucose levels has been described [17].…”

Section: Maternal Energy Metabolism and Acid Base Balancementioning

confidence: 99%

Fetal and maternal energy metabolism during labor in relation to the available caloric substrate

Scheepers¹,

Jong²,

Essed³

et al. 2001

Journal of Perinatal Medicine

View full text Add to dashboard Cite

show abstract

“…Labor is characterized by increased concentrations of nutrients including glucose (1–5), free fatty acids(3;6), ketone bodies(7), and lactic acid. (8) There is an approximately 3-fold increase in whole body glucose utilization during labor and delivery and, as expected, energy expenditure of the parturient women in the second stage of labor is 40% higher compared to the first stage.…”

Section: Introductionmentioning

confidence: 99%

Characterization of visceral and subcutaneous adipose tissue transcriptome in pregnant women with and without spontaneous labor at term: implication of alternative splicing in the metabolic adaptations of adipose tissue to parturition

Mazaki‐Tovi

Tarca

Vaisbuch

et al. 2016

Journal of Perinatal Medicine

View full text Add to dashboard Cite

OBJECTIVE The aim of this study was to determine gene expression and splicing changes associated with parturition and regions (visceral vs subcutaneous) of the adipose tissue of pregnant women. STUDY DESIGN The transcriptome of visceral and abdominal subcutaneous adipose tissue from pregnant women at term with (n=15) and without (n=25) spontaneous labor was profiled with Affymetrix GeneChip Human Exon 1.0 ST array. Overall gene expression changes and differential exon usage rate were compared between patient groups and adipose tissue regions (paired analyses). Selected genes were tested by quantitative reverse transcription–polymerase chain reaction. RESULTS Four hundred eighty-two genes were differentially expressed between visceral and subcutaneous fat of pregnant women with spontaneous labor at term (q-value <0.1; fold change >1.5). Biological processes enriched in this comparison included tissue and vasculature development, inflammatory and metabolic pathways. Differential splicing was found for 42 genes (q-value <0.1; difference FIRMA scores >2) between adipose tissue regions of women not in labor. Differential exon usage associated with parturition was found for three genes (LIMS1, HSPA5 and GSTK1) in subcutaneous tissues. CONCLUSION We show for the first time evidence of implication of mRNA splicing and processing machinery in the subcutaneous adipose tissue of women in labor compared to those without labor.

show abstract

Alterations of plasma free fatty acids and glucose during labor

Cited by 20 publications

References 8 publications

Medical Therapy for Pulmonary Arterial Hypertension

Medical Therapy for Pulmonary Arterial Hypertension

Fetal and maternal energy metabolism during labor in relation to the available caloric substrate

Characterization of visceral and subcutaneous adipose tissue transcriptome in pregnant women with and without spontaneous labor at term: implication of alternative splicing in the metabolic adaptations of adipose tissue to parturition

Contact Info

Product

Resources

About